Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Gastroenterology. 2015 Apr 14;149(1):201–210. doi: 10.1053/j.gastro.2015.04.010

Figure 1. Gemcitabine and a CD40 agonist synergize to induce T cell-dependent tumor regression in a transplantable model of pancreatic carcinoma.

Figure 1

(A) Healthy PC littermates were implanted subcutaneously on day 0 with a KPC-derived tumor cell line. On day 13, mice were treated with Gemcitabine (Gem) at 120 mg/kg or PBS followed 48 hours later by intraperitoneal injection of FGK45 or control IgG2a (each 100 μg). (B) Waterfall plot of tumor response for each animal (n>6 per group) determined by change in tumor volume measured 14 days after treatment. Gem/FGK45 vs PBS/IgG2a, P=0.005, Fisher's exact test. (C) Overall survival curves of the four experimental groups (n ≥ 6 per group). Gem/FGK45 vs PBS/IgG2a, P=0.0001, Gem/FGK45 vs PBS/FGK45, P=0.04; log-rank test. (D) Whisker plots showing quantification by immunohistochemistry of CD3, CD4, and CD8 cell infiltrates into tumors 14 days after the indicated treatment is shown (n = 4 per group). CD3, *P=0.018; CD4, *P=0.044; CD8, *P=0.022, **P=0.005, Student's t test (E) Healthy PC littermates (n ≥ 6 per group) were implanted and treated as in (A) with cohorts of mice also receiving depleting antibodies for CD4 (GK1.5) and CD8 (2.43) cells before and during treatment. Waterfall plot of tumor response determined by change in tumor volume is shown. Gem/FGK45 vs Gem/FGK45/GK1.5, P=0.001; Gem/FGK45 vs Gem/FGK45/2.43, P=0.015; Fisher's exact test.